Edition:
India

Dicerna Pharmaceuticals Inc (DRNA.OQ)

DRNA.OQ on NASDAQ Stock Exchange Global Select Market

15.83USD
1:30am IST
Change (% chg)

$0.03 (+0.19%)
Prev Close
$15.80
Open
$15.92
Day's High
$16.02
Day's Low
$15.69
Volume
60,811
Avg. Vol
171,806
52-wk High
$17.96
52-wk Low
$9.40

Latest Key Developments (Source: Significant Developments)

Dicerna Pharma Posts Q1 Loss Per Share Of $0.38
Friday, 10 May 2019 

May 9 (Reuters) - Dicerna Pharmaceuticals Inc ::DICERNA™ REPORTS FIRST QUARTER 2019 FINANCIAL AND OPERATING RESULTS AND PROVIDES CORPORATE UPDATE.Q1 LOSS PER SHARE $0.38.Q1 EARNINGS PER SHARE ESTIMATE $-0.23 -- REFINITIV IBES DATA.AS OF MARCH 31 HAD $371.2 MILLION IN CASH, CASH EQUIVALENTS AND HELD-TO-MATURITY INVESTMENTS.BELIEVES CURRENT CASH,OTHERS WILL BE SUFFICIENT TO FUND EXECUTION OF ITS CURRENT CLINICAL AND OPERATING PLAN BEYOND 2020.EXPECTS ITS OVERALL RESEARCH AND DEVELOPMENT EXPENSE TO CONTINUE TO INCREASE FOR FORESEEABLE FUTURE.  Full Article

Dicerna Submits Updated IND Application For DCR-PHXC For Treatment Of Primary Hyperoxaluria
Thursday, 2 May 2019 

May 2 (Reuters) - Dicerna Pharmaceuticals Inc ::DICERNA™ SUBMITS UPDATED IND APPLICATION FOR DCR-PHXC FOR TREATMENT OF PRIMARY HYPEROXALURIA (PH) FOR THE PHYOX™2 PIVOTAL TRIAL.DICERNA PHARMACEUTICALS INC - UPDATED IND APPLICATION FOR DCR-PHXC REFLECTS ALIGNMENT WITH FDA ON PATH TO FULL APPROVAL FOR TREATMENT OF PH1.DICERNA PHARMACEUTICALS INC - DISCUSSIONS NOW FOCUSING ON APPROPRIATE ENDPOINTS FOR PH2 AND PH3.DICERNA PHARMACEUTICALS INC - COMPANY EXPECTS TO BEGIN ENROLLING PATIENTS TO PHYOX2 TRIAL IN Q2 OF 2019.  Full Article

Dicerna Pharma Announces Initiation Of Participant Screening For Phyox2 Pivotal Trial In PH1 And PH2
Friday, 29 Mar 2019 

March 29 (Reuters) - Dicerna Pharmaceuticals Inc ::DICERNA™ ANNOUNCES THE PRESENTATION OF UPDATED DATA DEMONSTRATING UTILITY OF ITS LEAD COMPOUND DCR-PHXC IN TREATING PRIMARY HYPEROXALURIA TYPE 1 (PH1) AND TYPE 2 (PH2).DICERNA PHARMACEUTICALS INC - COMPANY ANNOUNCES INITIATION OF PARTICIPANT SCREENING FOR PHYOX2 PIVOTAL TRIAL IN PH1 AND PH2.DICERNA PHARMACEUTICALS INC - PHYOX™1 INVESTIGATORS REPORTED POTENT, DURABLE RESPONSE IN PHASE 1 STUDY IN PATIENTS WITH PH1 AND PH2.  Full Article

Boehringer Ingelheim Exercises Option On Second Hepatic Disease Target From Collaboration With Dicerna
Friday, 4 Jan 2019 

Jan 4 (Reuters) - Dicerna Pharmaceuticals Inc ::BOEHRINGER INGELHEIM EXERCISES OPTION ON SECOND HEPATIC DISEASE TARGET FROM RESEARCH COLLABORATION WITH DICERNA.DICERNA PHARMACEUTICALS INC - OPTION IS SECOND TARGET UNDER TWO COMPANIES' RESEARCH COLLABORATION AND LICENSE AGREEMENT.DICERNA PHARMACEUTICALS - COLLABORATION SEEKS TO DEVELOP NOVEL TREATMENTS FOR CHRONIC LIVER DISEASES, INCLUDING NONALCOHOLIC STEATOHEPATITIS (NASH).DICERNA PHARMACEUTICALS - UNDER AGREEMENT TERMS, BOEHRINGER INGELHEIM WILL BE RESPONSIBLE FOR FUTURE CLINICAL DEVELOPMENT OF THE THERAPEUTIC TARGET.  Full Article

Dicerna Pharmaceuticals Says Co, Boehringer Ingelheim International GmbH Entered Additional Target Agreement
Friday, 4 Jan 2019 

Jan 4 (Reuters) - Dicerna Pharmaceuticals Inc ::DICERNA PHARMACEUTICALS INC - ON DEC 31, CO, AND BOEHRINGER INGELHEIM INTERNATIONAL GMBH, ENTERED AN ADDITIONAL TARGET AGREEMENT - SEC FILING.DICERNA PHARMACEUTICALS INC - COMPANY HAD CASH, CASH EQUIVALENTS, AND HELD-TO-MATURITY INVESTMENTS OF APPROXIMATELY $302.6 MILLION AS OF DECEMBER 31, 2018..DICERNA PHARMACEUTICALS - BOEHRINGER INGELHEIM INTERNATIONAL GMBH WILL PAY CO A NON-REFUNDABLE UPFRONT PAYMENT OF $5.0 MILLION.DICERNA PHARMACEUTICALS - ATA PROVIDES BI WITH OPTION TO ADD DEVELOPMENT OF PRODUCT CANDIDATES TARGETING A FURTHER ADDITIONAL GENE FOR A 3-YEAR PERIOD.DICERNA PHARMACEUTICALS - CO ELIGIBLE TO RECEIVE UP TO $170.0 MILLION IN POTENTIAL DEVELOPMENT AND COMMERCIAL MILESTONES RELATED TO ADDITIONAL TARGET.DICERNA PHARMACEUTICALS - ELIGIBLE TO RECEIVE TIERED ROYALTY PAYMENTS ON POTENTIAL GLOBAL NET SALES, SUBJECT TO CERTAIN ADJUSTMENTS, IN MID-SINGLE DIGITS.DICERNA - BELIEVES CASH, CASH-EQUIVALENTS, PAYMENTS FROM LILLY & REDUCED BY CASH PAYMENT TO ALNYLAM IS SUFFICIENT TO FUND OPERATING PLAN BEYOND 2020.DICERNA PHARMACEUTICALS -ATA PROVIDES FOR DELIVERY OF A REPLACEMENT CANDIDATE TO BI IF A PRODUCT CANDIDATE OR ATA FAILS AT SOME STAGES OF DEVELOPMENT.  Full Article

Dicerna Pharmaceuticals Inc - Co Will Be Added To Nasdaq Biotechnology Index .
Thursday, 20 Dec 2018 

Dec 20 (Reuters) - Dicerna Pharmaceuticals Inc ::DICERNA PHARMACEUTICALS INC - COMPANY WILL BE ADDED TO NASDAQ BIOTECHNOLOGY INDEX EFFECTIVE PRIOR TO MARKET OPEN ON MONDAY, DECEMBER 24, 2018..  Full Article

Dicerna Qtrly Loss Per Share $0.35
Tuesday, 6 Nov 2018 

Nov 5 (Reuters) - Dicerna Pharmaceuticals Inc ::DICERNA REPORTS THIRD QUARTER 2018 FINANCIAL AND OPERATING RESULTS AND PROVIDES CORPORATE UPDATE.DICERNA PHARMACEUTICALS INC - ON TRACK TO INITIATE REGISTRATION TRIAL IN Q1 2019 FOR DCR-PHXC IN PRIMARY HYPEROXALURIA.DICERNA PHARMACEUTICALS INC - AS OF SEPTEMBER 30, 2018, DICERNA HAD $180.4 MILLION IN CASH, CASH EQUIVALENTS AND HELD-TO-MATURITY INVESTMENTS.DICERNA PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.35.DICERNA PHARMACEUTICALS INC - QTRLY REVENUE FROM COLLABORATIVE ARRANGEMENTS $1.5 MILLION.  Full Article

Alexion And Dicerna Announce Collaboration To Discover And Develop RNAi Therapies For Complement-Mediated Diseases
Wednesday, 24 Oct 2018 

Oct 24 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION AND DICERNA ANNOUNCE COLLABORATION TO DISCOVER AND DEVELOP RNAI THERAPIES FOR COMPLEMENT-MEDIATED DISEASES.DICERNA PHARMACEUTICALS INC - DICERNA TO RECEIVE UPFRONT PAYMENT OF $22 MILLION AND EQUITY INVESTMENT OF $15 MILLION.DICERNA PHARMACEUTICALS INC - DEAL HAS POTENTIAL FOR ADDITIONAL MILESTONE-DEPENDENT AND ROYALTY PAYMENTS.DICERNA PHARMACEUTICALS - ALEXION MAKING A CONCURRENT $15 MILLION EQUITY INVESTMENT IN DICERNA AT A PREMIUM TO MARKET AS OF COLLABORATION EFFECTIVE DATE..DICERNA - COLLABORATION ALSO PROVIDES FOR POTENTIAL ADDITIONAL DEVELOPMENT AND APPROVAL-RELATED MILESTONE PAYMENTS OF UP TO $105 MILLION PER TARGET.DICERNA PHARMACEUTICALS INC - COLLABORATION ALSO PROVIDES FOR SALES MILESTONES AND MID-SINGLE TO LOW-DOUBLE DIGIT ROYALTIES ON FUTURE PRODUCT SALES..  Full Article

Dicerna Pharmaceuticals Q1 Loss Per Share $0.30
Tuesday, 15 May 2018 

May 14 (Reuters) - Dicerna Pharmaceuticals Inc ::DICERNA REPORTS FIRST QUARTER 2018 FINANCIAL AND OPERATING RESULTS AND PROVIDES CORPORATE UPDATE.DICERNA PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.30.DICERNA PHARMACEUTICALS INC - BELIEVES THAT IT HAS SUFFICIENT CASH TO FUND EXECUTION OF ITS CURRENT CLINICAL AND OPERATING PLAN THROUGH 2019.DICERNA PHARMACEUTICALS INC - FOR THREE-MONTH PERIOD ENDED MARCH 31, 2018, DICERNA RECOGNIZED $1.5 MILLION OF REVENUE ASSOCIATED WITH BI AGREEMENT.  Full Article

Ecor1 Capital Llc Reports a 9.4 Percent Passive Stake In Dicerna Pharmaceuticals
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Dicerna Pharmaceuticals Inc ::ECOR1 CAPITAL, LLC REPORTS A 9.4 PERCENT PASSIVE STAKE IN DICERNA PHARMACEUTICALS AS OF DEC 20, 2017.  Full Article